EU, U.S. and Japanese regulators join forces on antibiotic trials
16 June 2017
The three drug regulators from Europe, the U.S. and Japan have come together in a data share program aimed at boosting antibiotic development. Long held as one of the most overlooked but potentially devastating areas of development, antibiotic resistance and a lack of new meds in this area have increasingly become a major concern for governments.
Want to earn more, pharma reps? Go large, get on the road or jump to biotech
15 June 2017
The place to be in drug sales is biotech. Yet another year’s worth of salary and bonus data show that biotech reps are outearning every category in the medical sales field save health IT.
Percentage of Russian-made drugs in healthcare procurement reached 72.4% in Q1
14 June 2017
According to the hospital audit of Russian pharmaceutical market conducted by DSM Group, 203.9 million packages of medicinal products worth 45.9 billion rubles were purchased for healthcare facilities in Q1 2017.
List of manufacturers participating in the Russian project on drug labelling
13 June 2017
The experiment on labeling certain medicinal products for human use with control (identification) marks and monitor their circulation is conducted in the Russian Federation from February 1 to December 31, 2017.
Russia elaborates a strategy for microorganisms resistance to medicinal products
13 June 2017
The Ministry of Health of the Russian Federation elaborated a draft law “On the Approval of the Strategy for Preventing and Overcoming the Resistance of Microorganisms and Noxious Organisms of Plants to Medicinal Products, Chemicals and Biologics for the Period until 2030 and Beyond.”
08 June 2017
Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced that, today Charles C. Wykoff , MD, PhD, presented preliminary results from a non-interventional and retrospective trial (the “Extension Study”) of patients who had participated in the completed Phase 2 trial of CLS-TA for suprachoroidal administration (“suprachoroidal CLS-TA”). 74% of RVO Patients Receiving CLS-TA for Suprachoroidal Administration Together with Intravitreally Administered EYLEA® Did Not Receive Any Additional Treatment Over 9 Months.
Why biosimilars are changing the pharmaceutical industry
07 June 2017
We caught up with Celltrion Healthcare‘s Ho-ung Kim to find out how biosimilars cut costs, increase access to medicine and are ultimately changing the industry…
Drug Prices Become Target for FDA as Chief Expands Purview
06 June 2017
The head of the U.S. Food and Drug Administration is considering using the agency’s powers to bring more price competition to the market for generic drugs, targeting high-priced products by prioritizing the approval of additional competing treatments.
06 June 2017
On May 31, 2017, the European Medicines Agency (EMA) and the European Commission published guidance on how pharmaceutical companies can prepare for Brexit. The guidance offers information on centralized procedures and other agency activities. The guidance is one in a series of guidance documents the agency plans to publish on the effects of the United Kingdom’s withdrawal from the European Union.
05 June 2017
Over the last few months it hasn’t been unusual to see new combination studies being announced on a daily basis, matching one of the 5 approved PD-(L)1 checkpoint drugs with another cancer therapy. Some mornings they come in pairs.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Achieving FAIR bacterial identification
18 April 2024
Unique testing regimen could prevent nuclease contamination
18 April 2024
CRISPR technologies fuelling haematological innovations
17 April 2024
17 April 2024